ALung Systems announces closing of $14 Million Series A financing round ALung Technology.

ALung Systems announces closing of $14 Million Series A financing round ALung Technology, Inc. Today announced that the Company has closed a $14 Million Series A financing round. THE BUSINESS’S Hemolung device is expected to help many individuals with acute respiratory failure in order to avoid intubation and invasive mechanical ventilation. This treatment is usually expected to provide a significant benefit over intubation and mechanical ventilation, for the reason that it will permit the patient to talk and eat, and prevent sedation, while offering the lungs the opportunity to heal. Related StoriesTeva presents new Reslizumab data at European Respiratory Culture International Congress 2015Study raises expect reducing life-threatening respiratory problems in infantsPhilips showcases latest patient-driven sleep and respiratory solutions at the European Respiratory Culture International Congress 2015’This financing allows ALung to full its scientific trial in Germany and subsequently commercialize the Hemolung System,’ said Peter DeComo, CEO and Chairman of ALung.Although 60 percent of cancers occur in patients over 65, their participation in clinical trials does not exceed 25 per cent. This has made it challenging to predict how older sufferers will tolerate and react to the latest cancer treatments and has offered an obstacle to making evidence-based clinical decisions. Dr Domingo and her colleagues teamed up with experts from the University of Barcelona to check out 224 patients diagnosed with cancerous tumours. The sufferers ranged from 32 to 92 years of three-quarters and age of these were male.